Cognition Therapeutics Announces Positive Phase 2 Trial Results

Cognition Therapeutics ( (CGTX) ) just unveiled an update.

On May 8, 2025, Cognition Therapeutics announced topline results from its Phase 2 MAGNIFY trial of zervimesine in adults with geographic atrophy secondary to dry age-related macular degeneration. The trial showed that zervimesine treatment slowed the rate of lesion growth by 28.6% compared to placebo, with a 28.2% reduction in lesion size at 18 months. These results suggest zervimesine’s potential as a transformative oral treatment for degenerative diseases, offering an alternative to current injectable options. The trial concluded early to focus resources on ongoing programs in Alzheimer’s and dementia with Lewy bodies.

Spark’s Take on CGTX Stock

According to Spark, TipRanks’ AI Analyst, CGTX is a Neutral.

Cognition Therapeutics is currently facing major financial challenges with persistent losses and cash flow issues. Technical indicators provide mixed signals with short-term momentum but long-term caution. Valuation remains a concern with negative earnings and no dividend yield. Although the earnings call highlighted some strategic progress, significant concerns like NASDAQ compliance and uncertain funding overshadow these advancements. Overall, the stock is a high-risk investment with potential for future improvement if financial and strategic objectives are met.

To see Spark’s full report on CGTX stock, click here.

More about Cognition Therapeutics

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system. Their lead candidate, zervimesine (CT1812), is being investigated in clinical programs for dementia with Lewy bodies and Alzheimer’s disease.

Average Trading Volume: 1,294,099

Technical Sentiment Signal: Sell

Current Market Cap: $25.87M

Learn more about CGTX stock on TipRanks’ Stock Analysis page.